News

24 September 2015; Company Announcement Pro Medicus Signs AHN - Acrobat pdf 88k Key Points: Allegheny Health Network (AHN) to use Pro Medicus’ Visage 7 technology for primary diagnoses and clinical distribution of medical images Five-year deal with base value to PME in excess of A$11 million AHN is a subsidiary of Highmark Health, which is Blue Cross Blue Shield-affiliated The Highmark Health enterprise is the 3rd largest health care delivery & financing system in America Transaction-based model with potential upside Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly owned US subsidiary, Visage Imaging Inc, has signed an A$11 million five-year contract with Allegheny Health Network (“AHN”). AHN is a subsidiary of Highmark Health, the 3rd largest health care delivery & financing system in America, which is affiliated with Blue Cross Blue Shield. The contract will see Pro Medicus’ Visage 7 technology used for primary diagnosis across AHN, as well as clinical distribution of diagnostic images to 2,800 physicians throughout the AHN network via a single point of access to the AHN EHR. AHN is a unified system comprised of eight hospitals, including Allegheny General Hospital, Allegheny Valley Hospital, Canonsburg Hospital, Forbes Hospital, Jefferson Hospital, Saint Vincent Hospital, Westfield Memorial Hospital and West Penn Hospital. AHN’s integrated care portfolio has an urban, academic and community focus, including over 2,000+ beds and more than 200 locations. AHN is one of the largest health networks in the Pittsburgh metro area, providing care to 29 Pennsylvania counties, as well as portions of New York, Ohio and West Virginia. “Visage 7’s prominence in enterprise imaging exemplifies the world class capabilities that we’re bringing to AHN,” said Dr Paul M. Kiproff, Chair, AHN Department of Radiology.

PME CEO on Full-Year Results Open Briefing - Acrobat pdf 425k 21 August 2015 Open Briefing interviewed Pro Medicus CEO, Dr Sam Hupert, discussing the latest PME Full-Year Results.    

Pro Medicus Limited Full-Year Results 2014-15 - Acrobat pdf 146k 21 August 2015 Key Points: Profit up 113.2% to $3.22 million Revenue up 21.7% to 17.58 million US operations key driver of profit increase Cash balance $12.94 million after tax on Amira sale and dividends Company remains debt-free 1c per share (unfranked) final dividend making total for year of 2c per share (unfranked) Leading medical imaging company, Pro Medicus Limited [ASX: PME] today announced its full- year results for the year to 30 June 2015. Profit for the year was $3.22 million, up 113.2% on the previous corresponding period. Annual revenue was $17.58 million, up 21.7% on the previous corresponding period. Margins increased as a result of US contract revenue as well as a positive currency impact. At year end, the company’s cash reserves were $12.94 million after paying $3.74 million tax on the Amira sale announced in 2012 and dividend payout of $2.00 million. Directors declared a final unfranked dividend of 1c a share, making a total for the year of 2c a share, unfranked. Pro Medicus Chief Executive Officer Dr Sam Hupert said 2014-15 was a year in which Pro Medicus built on the momentum from the previous year. The company made several key announcements which further underlined the leading position of the company’s imaging technology and its gathering acceptance across international health markets. 20 November 2014 – WellSpan Health Pro Medicus announced the signing of an A$8 million seven-year contract with WellSpan Health, a large regional health network in the northeastern United States. Under the contract, WellSpan agreed to use Pro Medicus’ Visage 7 technology as a core component of its new enterprise imaging platform for at least the next seven years. 12 January

 Pro Medicus Receives FDA Clearance for Visage Ease Pro - Acrobat pdf 105k 19 May 2015 Leading imaging IT provider, Pro Medicus Limited [ASX: PME], today announced its wholly-owned US subsidiary Visage Imaging Inc has received US Food and Drug Administration (FDA) 510 (k) clearance for its Visage Ease Pro mobile app technology. Visage Ease Pro has been certified for diagnostic interpretation of all imaging modalities apart from mammography which requires higher screen resolution than current mobile devices can support. “With Visage Ease, our current mobile app, we lead the pack in terms of speed and functionality for review access of images. Our new Pro version has raised the bar even further. Incorporating the ability to quickly check the calibration of the screen of an iOS device means that radiologists and allied physicians that require full diagnostic capability on the go can now have it on their mobile device. This enables them to securely interpret images no matter how large they are anywhere using Visage technology.” Visage Ease Pro includes numerous image manipulation features, display of non-DICOM (and non-diagnostic) images such as photos, support for recording voice memos, and the ability to upload photo attachments to studies on Visage 7. Dr Hupert said: “FDA clearance represented the culmination of 12 months of regulatory negotiations. We join only a handful of other mobile applications that have received FDA approval but we believe ours is the only FDA approved mobile solution that is an integral part of a total enterprise imaging platform.” Dr Hupert also said that the technology has been approved for use in Australia by the Therapeutic Goods Administration, as well as in Canada and Europe. “This approval worldwide represents further validation of the extent and functionality

Pro Medicus Signs A$9.5 Million Deal with University of Florida Health Network - Acrobat pdf 128k 21 April 2015 Key Points: UF Health to use Visage 7 technology for primary diagnosis and clinical distribution of medical images Seven-year deal, with base value to PME of A$9.5 million Significant win at prestigious university/academic institution Hybrid of capital and transaction-based models with potential upside Leading imaging IT provider, Pro Medicus Limited [ASX: PME] today announced its wholly owned US subsidiary, Visage Imaging Inc., has signed a A$9.5 million seven-year contract with University of Florida Health — a large university health system in Northern Florida. The deal furthers the penetration of Visage 7 technology in the university/academic hospital space, a key area of the North American enterprise imaging market. The contract will see Pro Medicus’ Visage 7 technology used for primary diagnosis across UF Health, as well as clinical distribution of diagnostic images to thousands of physicians throughout the UF Health care network. UF Health comprises two health campuses: UF Health Shands Hospital in Gainesville, FL, incorporating UF Health Shands Cancer Hospital and UF Health Shands Children’s Hospital, and UF Health Jacksonville in Jacksonville, FL. UF Health provides comprehensive high-quality patient care, from primary care and family medicine to subspecialty tertiary and quaternary services for patients with highly complex medical conditions. The faculty of the UF College of Medicine includes internationally recognised physicians whose expertise is supported by intensive research activities. Each year patients come to UF Health from around the world, across the US, and from all 67 Florida counties. “After 18 - 24 months of careful analysis by a team of technologists, physicists, radiologists and clinical providers we are happy to be working with Visage to provide the visualization

On-Market Share Buy-Back - Acrobat pdf 685k 17 March 2015 On 18 March 2014, leading health imaging company Pro Medicus (ASX: PME) announced the implementation of an on-market share buy-back for a period of 12 months. The attached Appendix 3F confirms the finalisation of that buy-back. Also attached is an Appendix 3C to announce the commencement of a new on-market share buy-back, permitting the Company to acquire up to 10% of the ordinary shares on issue during the last 12 months. In accordance with the Corporations Act, acquisitions under the on-market buy-back cannot commence until 14 days after notice has been given to ASIC, which is from 1 April 2015.

PME CEO on H1 Results Open Briefing - Acrobat pdf 255k 20 February 2015 Open Briefing interviewed Pro Medicus CEO, Dr Sam Hupert, discussing the latest PME Interim Results.    

Pro Medicus Announces Interim Results - Acrobat pdf 113k 20 February 2015 Key Points: First-half net profit increased to $1.61 million from $0.2 million in previous corresponding period Revenue $8.64 million – 42.5% higher than previous corresponding period Cash reserves $14.6 million at 31st December 2014 Revenue flowing from first of three recent US deals Company remains debt-free Interim dividend of 1 cent per share (unfranked) Leading health imaging company, Pro Medicus Limited [ASX: PME] today announced a first-half after-tax profit of $1.61 million for the six months to the end of December 2014, a significant increase over the previous corresponding period. The result from the underlying operations for the period was a profit of $0.98m compared to an underlying profit of $0.2m from the previous corresponding period. Revenue from ordinary activities was $8.64 million – a 42.5% increase over the previous corresponding period. The Company’s Board has resolved to pay an unfranked interim dividend of 1 cent per share. The Company's cash reserves totalled $14.6 million at the end of the period. Dr Sam Hupert, CEO of Pro Medicus, said he was delighted with the Company’s progress during the past six-month period. “Both revenue and profits have improved substantially and we expect this to continue as we phase in our recent US contract wins, the first of which started to contribute to this half’s result. It was also very pleasing to see ongoing improvements in our Australian operations as we rollout our new Visage RIS platform to both existing and new clients.” In summary, the major US sales were: 22 April 2014 A large US health network agreed to use Pro Medicus’ Visage 7 enterprise imaging platform for primary diagnoses and distribution of medical images. Six-year

PME Signs $5M Deal with Zwanger-Pesiri - Acrobat pdf 115k 12 January 2015 Key Points: Zwanger-Pesiri to use Pro Medicus’ Visage 7 for primary diagnoses and clinical distribution of medical images. Five-year deal, with base value to PME of A$5 million (US$4.1 million). Transaction-based model with potential upside. Further reinforces Visage’s position in the private outpatient (Imaging Centre) market. Leading imaging IT company Pro Medicus Limited [ASX: PME] today announced the signing of an A$5 million (US$4.1 million) five-year contract with Zwanger-Pesiri Radiology (“Zwanger-Pesiri”) – a highly respected radiology group and outpatient imaging provider on New York’s Long Island. The group will use Pro Medicus’ Visage 7 enterprise viewer technology as the core component of its Deconstructed PACS® enterprise imaging strategy enabling the group to provide exceptionally fast, state-of-the-art imaging to their reading radiologists and referring physicians. Zwanger-Pesiri is one of the largest US providers of outpatient imaging services with 18 imaging centers and 58 radiologists, regionally distributed across Long Island. The group is known for acquiring the latest in advanced imaging technology being the first private radiology practice in the US to purchase a PET/MRI (positron emission tomography/magnetic resonance imaging) scanner. This is in addition to significant recent investments in 3D mammography or digital breast tomosynthesis (DBT) and other leading edge technologies. “Based on the continued growth of the Zwanger-Pesiri imaging center network, and our strategic investment in the latest modalities, it was apparent that our legacy PACS could not keep up with our needs,” said Dr Steven L. Mendelsohn, CEO. “We are committed to using the most advanced technology and did an extensive review of the available systems on the market. Once we experienced what Visage 7 offered, using our own studies across our own network,

Pro Medicus and Visage Imaging at RSNA 2014 To all of our guests and global customers, thank you for making RSNA 2014 such a tremendous success for Pro Medicus and Visage Imaging!  We enjoyed spending time with you in our newly enlarged RSNA booth, listening to your challenges, your aspirations and strategies for enterprise imaging for 2015.  As has become a bit of tradition, we’ve crafted our “top five” observations coming out of the industry’s largest, most anticipated trade show of the year.  And if you didn’t attend RSNA, we hope you find the observations insightful: 1.  The Lines Have Been Drawn At RSNA 2014, it’s quite clear that there are two technology camps—you are either a legacy PACS or you aren’t.  The market now sees through PACS vendor ‘marketecture’ of vague jargon and creative massaging of buzzwords to fit their agenda du jour. The terms “enterprise/universal viewer", “VNA", and "enterprise worklist” are not native to PACS and merely a marketing reaction to the concept of deconstructing a PACS.  All of a sudden, systems that were developed as a silo’d PACS (many in fact, developed last century) are now being marketed as VNA, as universal viewers, and enterprise worklists.  The fact is, these systems weren’t designed as modular components, were never intended to be plug-n-play with third-party systems and never will be.   Square peg, round hole. PACS archives pitched as independent VNAs?  PACS diagnostic workstations suddenly promoted as universal?  PACS-driven workflow offered as enterprise capable?  Also, layer after layer of image viewers on top of thick-client PACS, with dated architectures, are far from ideal.  Layers are great when you live in Minnesota to keep you warm and cozy, but in PACS, too many